(RTTNews) - argenx (ARGX) announced preliminary global product net sales for full-year 2025 of approximately $4.15 billion, up 90% from prior year. Preliminary global product net sales for the fourth quarter was approximately $1.29 billion. argenx said it continues to advance Vision 2030. The company noted that, by the end of 2026, the argenx pipeline will include four Phase 3 molecules and a total of 10 molecules in clinical development.
"Looking at the year ahead, we will expand our FcRn franchise and report the first Phase 3 data for our next potential blockbuster medicine, with four registrational readouts across both efgartigimod and empasiprubart," said Tim Van Hauwermeiren, CEO of argenx.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
